🇺🇸 LLY — Eli Lilly and Company

Salud Compra
← Volver

Precio actual

1.409,38 USD

Máx. histórico

1.417,54

4 días

Split 2:1 del 16/10/1997

Caída desde máximo

-0,58%

Rango 52 semanas

850,51 – 1.449,68

Variación hoy

-0,11%

Cierre anterior

1.410,99

Rango de hoy

1.393,61 – 1.437,00

Volumen hoy

2.713.999

Peor caída histórica

-68,26%

08/08/2000 → 05/03/2009

Recuperado en 2064 días

Volatilidad anualizada ⓘ

27,61%

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
45,74 (puede no estar actualizado)
Dividend yield
0,49% (puede no estar actualizado)
Precio objetivo analistas
1.442,09 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 1 día
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,47%
Fecha de pago Importe por participación
14/08/2026 1,7300 USD
15/05/2026 1,7300 USD
13/02/2026 1,7300 USD
14/11/2025 1,5000 USD
15/08/2025 1,5000 USD
16/05/2025 1,5000 USD
14/02/2025 1,5000 USD
15/11/2024 1,3000 USD
15/08/2024 1,3000 USD
15/05/2024 1,3000 USD
14/02/2024 1,3000 USD
14/11/2023 1,1300 USD
14/08/2023 1,1300 USD
12/05/2023 1,1300 USD
14/02/2023 1,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/03/2021 183,70 183,84 179,82 180,17 -1,91% 2,19% 3.931.500
23/03/2021 185,35 186,66 183,25 183,68 -1,16% 1,84% 3.284.700
22/03/2021 184,05 185,91 183,20 185,84 +0,84% 1,47% 2.666.600
19/03/2021 184,70 185,80 183,88 184,29 +0,20% 1,04% 6.048.600
18/03/2021 186,02 187,09 183,80 183,93 -1,50% 1,77% 4.240.000
17/03/2021 189,73 189,83 186,56 186,73 -2,18% 1,72% 5.134.200
16/03/2021 191,54 191,62 187,23 190,90 +0,92% 2,29% 6.194.200
15/03/2021 193,01 193,18 188,20 189,16 -9,09% 2,58% 12.388.500
12/03/2021 204,89 208,46 202,28 208,08 +1,40% 3,02% 4.541.400
11/03/2021 206,51 207,25 204,27 205,21 -0,12% 1,44% 4.037.300
10/03/2021 206,89 208,04 204,39 205,45 -0,32% 1,76% 3.400.200
09/03/2021 208,34 212,16 206,06 206,11 -0,44% 2,93% 4.227.300
08/03/2021 207,00 210,89 206,32 207,03 +0,05% 2,21% 3.300.300
05/03/2021 201,02 207,67 200,88 206,92 +3,18% 3,38% 3.875.900
04/03/2021 203,79 204,74 198,61 200,54 -0,72% 3,01% 4.308.400
03/03/2021 203,37 204,31 199,71 202,00 -1,05% 2,26% 3.660.300
02/03/2021 208,89 209,95 204,10 204,14 -1,13% 2,80% 3.445.300
01/03/2021 205,78 208,24 204,78 206,47 +0,77% 1,68% 2.797.400
26/02/2021 206,70 206,99 202,06 204,89 +0,52% 2,39% 3.887.900
25/02/2021 203,57 205,55 201,75 203,82 -0,34% 1,87% 2.386.700
24/02/2021 201,67 206,46 201,63 204,52 +1,01% 2,40% 2.848.800
23/02/2021 200,31 204,31 198,68 202,48 +0,90% 2,81% 3.287.700
22/02/2021 199,18 201,61 197,96 200,68 -0,12% 1,83% 2.263.600
19/02/2021 201,13 202,88 200,33 200,92 -0,10% 1,27% 3.434.900
18/02/2021 205,30 205,42 200,95 201,12 -2,59% 2,18% 3.919.400
17/02/2021 205,01 206,69 204,27 206,46 +0,34% 1,18% 3.329.900
16/02/2021 205,98 207,49 203,61 205,76 -0,74% 1,88% 2.741.900
12/02/2021 201,65 208,22 201,15 207,29 +2,33% 3,51% 2.611.300
11/02/2021 202,87 204,18 201,62 202,58 -0,89% 1,26% 3.544.700
10/02/2021 204,47 205,55 201,64 204,39 +1,33% 1,91% 3.062.700